US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Conduit Pharmaceuticals Inc.

0.0097

-0.0020-17.09%

Volume:7.72K

Turnover:76.87

Market Cap:- -

PE:- -

High:0.0117

Open:0.0117

Low:0.0096

Close:0.0117

Loading ...

Overview Company News Filings

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals announces new addition to autoimmune pipeline

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDTTW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDTTW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDTTW\",,,,,undefined,":{"symbol":"CDTTW","market":"US","secType":"STK","nameCN":"Conduit Pharmaceuticals Inc.","latestPrice":0.0097,"timestamp":1744920000000,"preClose":0.0117,"halted":0,"volume":7723,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.002,"latestTime":"04-17 16:00:00 EDT","open":0.0117,"high":0.0117,"low":0.0096,"amount":76.8711,"amplitude":0.179487,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0117,"volumeRatio":1.197735756157824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDTTW\",,,,,undefined,":{"symbol":"CDTTW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.197735756157824,"shares":0,"dividePrice":0,"high":0.0117,"amplitude":0.179487,"preClose":0.0117,"low":0.0096,"week52Low":0.0056,"pbRate":"--","week52High":0.1,"institutionHeld":0,"latestPrice":0.0097,"eps":0,"divideRate":0,"volume":7723,"delay":0,"ttmEps":0,"open":0.0117,"prevYearClose":0.0059,"prevWeekClose":0.0124,"prevMonthClose":0.0092,"prevQuarterClose":0.0092,"fiveDayClose":0.0125,"twentyDayClose":0.0125,"sixtyDayClose":0.0126},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDTTW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526698716","title":"Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698716","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698716?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA  which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships.This innovative approach differentiates Conduit's intellectual property from existing formulation patents, offering potential partners a next generation tapinarof asset with what the Company estimates to be extensive commercial viability. This comes at a critical juncture for VTAMA, a drug that has demonstrated blockbuster potential through Organon's $1.2 billion acquisition from Dermavant Sciences yet could face imminent generic competition upon exclusivity expiry in 2027. The timing is particularly strategic in the Company’s view, with tapinarof now entering clinical trials for cutaneous lupus and showing promise across multiple other inflammatory and autoimmune indications. Conduit's novel a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-novel-cocrystal-123000026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW","BK4121"],"gpt_icon":0},{"id":"2526695845","title":"Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2526695845","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526695845?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288200,"startTime":"0","endTime":"0","summary":"NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025  -- Conduit Pharmaceuticals Inc.   today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value.Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and will be subject to market conditions, corporate liquidity requirements, regulatory considerations, and other factors.The share repurchase program does not obligate the Company to acquire a particular amount of common stock and the Company will use its discretion to repurchase shares. The program has no fixed expiration date and may be adjusted or terminated at any ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-1-000-123000617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CDTTW","CDT"],"gpt_icon":0},{"id":"2525488220","title":"Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2525488220","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525488220?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:30","pubTimestamp":1744029000,"startTime":"0","endTime":"0","summary":"Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025  -- Conduit Pharmaceuticals Inc.   today announces that it has entered into an additional license and use agreement  withSarborg Limited to expand the scope of work on Conduit’s acquired AstraZeneca assets, includingAZD1656, AZD5658, and AZD5904.Under the agreement,Sarborgwill apply its proprietarymachine learning algorithmsto conduct an in-depth analysis of Conduit’s clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-expands-partnership-sarborg-123000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW"],"gpt_icon":0},{"id":"2523941750","title":"Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941750?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025  -- Conduit Pharmaceuticals Inc.   today announces that the United States Patent and Trademark Office  has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection now secured, the Company is strategically positioned to advance AZD1656 into clinical development, with clinical trial plans now in final stages of preparation.Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-receives-u-patent-123000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW"],"gpt_icon":0},{"id":"2520181351","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181351?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth.At its research and development facility at Cambridge Science Park, Conduit is enhancing its IP portfolio and optimize the formulation of its pipeline assets. In the laboratory, the Company is evaluating the assets licensed through the AstraZeneca partnership and other assets of critical interest. Significant progress has also been made in securing intellectual property  protection for Conduit’s lead asset, AZD1656. Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office  and IP Australia, with pending applications at the USPTO and European Patent Office, and other global patent offices, expected to be approved early in the second quarter. In addition, Conduit is actively worki","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-provides-research-development-123000754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1481600234.SGD","BK4121","LU1481599808.USD","LU1487256676.USD","SLE","LU2463526074.USD","BK4077","BK4097","BK4585","PRGS","IP","BK4136","CDT","BK4588","LU2065732104.USD","CDTTW"],"gpt_icon":0},{"id":"2517102384","title":"Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517102384","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517102384?lang=en_us&edition=fundamental","pubTime":"2025-03-07 17:53","pubTimestamp":1741341217,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now.In this article, we are going to take a look at where Conduit Pharmaceuticals Inc.  stands against the other micro cap stocks.Just as we overlook loose change, micro-cap stocks are often ignored for larger, more dominant enterprises. Investors trying to play safe ignore the fact that every strong stock was once a micro-cap stock. This niche segment of the market offers higher risk and, if successful, higher returns, particularly present in emerging industries where there is potential to outperform peers.Thus, with low price valuations by the investors, these stocks will continue to offer returns that surpass the returns from private equity fund investments. In view of this, we will take a look at some of the best","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-inc-cdt-best-095337236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","SQQQ","USAW.SI","TSYW.SI",".IXIC","QID","NQmain","NVIW.SI","MNQmain","CDTTW","CDT","PSQ","USJW.SI","TQQQ","CDTDA","BK4121"],"gpt_icon":1},{"id":"2509533743","title":"Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2509533743","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509533743?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":"Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio. The focus of Phase I was to establish a strong foundation for the collaboration with Sarborg, identify key inputs for the algorithmic approach, and align Sarborg’s services with Conduit’s strategic goals. The collaboration, initiated in December 2024, aims to revolutionize drug development by leveraging cutting-edge AI technologies to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring. Phase I included teach-in sessions with management, the validation of Conduit’s proprietary inputs that are critical for Sarborg’s cybernetic models and, thirdly, a comprehensive market analysis of cocrystal candidates.Conduit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-transitions-phase-ii-130000318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","BK4121","CDTTW"],"gpt_icon":0},{"id":"2506996305","title":"Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence","url":"https://stock-news.laohu8.com/highlight/detail?id=2506996305","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506996305?lang=en_us&edition=fundamental","pubTime":"2025-01-28 18:30","pubTimestamp":1738060200,"startTime":"0","endTime":"0","summary":"Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to expedite drug development, while continuing to advance its portfolio of proprietary assets to clinic.Conduit and Sarborg have completed the initial milestones including the Teach-in Sessions and Proprietary Inputs Validation, tailored to Conduit’s portfolio needs. These initial workstreams shape the integration of AI-driven processes to further strengthen Conduit’s ability to advance its proprietary assets, including AZD1656, AZD5904, AZD5658, CDT1656, and its AZD1656 cocrystals, with greater efficiency. While Conduit remains focused on delivering impactful therapies to patients through its proposed Phase 2 clinical trials in auto-immune disorders, the Company continually endeavours to remain at the forefront of innovation in pharmaceutical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-completes-strategic-review-103000836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CDTTW","CDT"],"gpt_icon":0},{"id":"2490005408","title":"Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2490005408","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490005408?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:30","pubTimestamp":1734006600,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring.This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio.By entering into this agreement with Sarborg, Conduit will address longstanding challenges in the pharmaceutical sector by seeking to reduce human error in critical decision-making processes including clinical development and asset identification. By integrating Sarborg’s algorithmic AI and cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving Conduit a significant competitive advantage.“By incorporating Sarborg’s cutting-edge AI and cybernetics platform, Conduit is taking a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-revolutionize-drug-development-123000853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CDT","CDTTW"],"gpt_icon":0},{"id":"2481503031","title":"Conduit Pharmaceuticals announces new addition to autoimmune pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2481503031","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481503031?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:40","pubTimestamp":1730810407,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals  announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders. The patent applications include a novel composition of matter filing for CDT1656, the newly introduced asset in Conduit’s portfolio. CDT1656 combines AZD1656 with a second compound whose mechanism of action plays a critical role in the progression of autoimmune disorders and has shown potential across a range of conditions. This combination provides an expansion to Conduit’s pipeline, creating an innovative addition to the Company’s autoimmune portfolio. Conduit believes that the development of CDT1656 has the potential to expand the market opportunity for the Company across a broader range of autoimmune conditions and patient subsets further strengthening its strategic position.Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements. Conduit ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6MInUe1T4fs5TaG11G3efw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6MInUe1T4fs5TaG11G3efw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-addition-autoimmune-124007357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-addition-autoimmune-124007357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW","BK4121"],"gpt_icon":0},{"id":"2480868583","title":"Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2480868583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480868583?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:45","pubTimestamp":1730493900,"startTime":"0","endTime":"0","summary":"SAN DIEGO and LONDON, Nov. 01, 2024  -- Conduit Pharmaceuticals Inc.  , today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited  and secured $1.2 million in new promissory notes through separate agreements with third parties.Conduit entered into a $2.65 million loan note with Nirland on August 6, 2024, which was subject to  a mandatory 75% repayment clause on new funding, and  a right of first refusal for Nirland on any future fundraising. Conduit and Nirland have re-negotiated the terms of the note to remove these restrictive clauses enabling Conduit flexibility to raise new financing. The note is now convertible at Nirland’s election at $0.10 per share, based on a multiple amount of the loan note that is then due and owing at the time of such conversion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-debt-restructuring-204500904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW","BK4121"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDTTW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDTTW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDTTW\",market:\"US\",delay:false,,,undefined,":{}}}